Coronary microvascular reperfusion injury and no-reflow in acute myocardial infarction

Clinical and Investigative Medicine

Volumn 30, Issue 3, 2007, Pages

  Kang, Sheng ^a,b   Yang, Yuejin ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Microvascular reperfusion injury; No reflow

Indexed keywords

ABCIXIMAB; ADENOSINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITROPRUSSIDE SODIUM; OXYGEN RADICAL; THIOL DERIVATIVE;

ACUTE HEART INFARCTION; AORTA BALLOON; ARTIFICIAL EMBOLISM; CALCIUM TRANSPORT; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; COUNTERPULSATION; ENDOTHELIAL DYSFUNCTION; FIBRINOLYTIC THERAPY; FLUID SHIFT; HEART MUSCLE INJURY; HEART SCINTISCANNING; HUMAN; MICROEMBOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBUS;

CORONARY CIRCULATION; ECHOCARDIOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

EID: 35948957438     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 241-3
2. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 2001;37:9-18.
3. Galiuto L, Lombardo A, Maseri A, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003; 89:731-7.
4. Nicklas JM, Gips SJ. Decreased coronary flow reserve after transient myocardial ischemia in dogs. J Am Coll Cardiol 1989; 13:195-9.
5. Bolli R, Triana JF, Jeroudi MO. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular "stunning". Circ Res 1990; 67: 332-43.
6. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54:1496-508.
7. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62:945-52.
8. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002; 87:162-8.
9. Colonna P, Cadeddu C, Montisci R, et al. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J 2002; 144:796-803.
10. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112:2143-8.
11. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70:200-11.
12. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-88.
13. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38: 291-300.
14. Niccoli G, Lanza GA, Shaw S, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006;27:1793-8.
15. Miller DD, Herrmann SC. Myocardial Infarction. In: Runge MS, Patterson C, eds. Principles of molecular cardiology: TOTOWA, NEW JERSEY: HUMANA PRESS, 2005:219-241.
16. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/ reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005;100:179-90.
17. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart 2004;90:123-5.
18. Kukreja RC, Weaver AB, Hess ML. Sarcolemmal Na(+)-K(+)-ATPase: inactivation by neutrophil-derived free radicals and oxidants. Am J Physiol 1990;259:H1330-6.
19. Agullo L, Garcia-Dorado D, Escalona N, et al. Hypoxia and acidosis impair cGMP synthesis in microvascular coronary endothelial cells. Am J Physiol Heart Circ Physiol 2002; 283:H917-25..
20. Saldanha C, Sargento L, Monteiro J, Perdigao C, Ribeiro C, Martins-Silva J. Impairment of the erythrocyte membrane fluidity in survivors of acute myocardial infarction. Clin Hemorheol Microcirc 1999;20:111-6.
21. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1339-46.
22. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
23. Akiba S, Kawauchi T, Oka T, Hashizume T, Sato T. Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation. Biochem Mol Biol Int 1998;46:1243-8.
24. Massberg S, Enders G, Eisenmenger S. Platelet-Endothelial Cell Interactions in the Postischemic Microvasculature. Messmer K (eds): Microcirculation in Chronic Venous Insufficiency. Prog Appl Microcirc. Basel, Karger, 1999; 23, 66-81.
25. Bustos M, Coffman TM, Saadi S, Platt JL. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 1997;100:1150-8.
26. Mizote I, Ueda Y, Ohtani T, et al. Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation 2005;112:1001-7.
27. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61:498-511.
28. Xiao CY, Hara A, Yuhki K, et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001;104: 2210-5.
29. Golino P, Ragni M, Cirillo P, et al. Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol 2000;278:H1507-16.
30. Kukreja RC, Janin Y. Reperfusion Injury: Basic Concepts and Protection Strategies. J Thromb Thrombolysis 1997;4:7-24.
31. Schmiedl A, Schnabel PA, Kausch Blecken von Schmeling H, Marten K, Richter J. Swelling of capillary endothelial cells and cardiomyocytes in the ischaemic myocardium of artificially arrested canine hearts. J Electron Microsc (Tokyo) 2001;50:349-57.
32. Vallance PJT, Webb DJ, eds. Vascular endothelium in human physiology and pathophysiology. Amsterdam, Netherlands: harwood academic publishers, 2000: 3-108.
33. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72.
34. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol 2003;284:H1134-41.
35. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction. Cardiovasc Res 2003;59: 715-22.
36. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc- facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol 2003; 98: 275-84.
37. Reffelmann T, Kloner RA. Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 2004;43:580-8.
38. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-9.
39. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
40. van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998; 97: 2302-2306.
41. Zalewski J, Zmudka K, Musialek P, et al. Detection of microvascular injury by evaluating epicardial blood flow in early reperfusion following primary angioplasty. Int J Cardiol 2004;96:389-96.
42. Iwakura K, Ito H, Nishikawa N, et al. Early temporal changes in coronary flow velocity patterns in patients with acute myocardial infarction demonstrating the "no-reflow" phenomenon. Am J Cardiol 1999;84:415-19.
43. Okamura A, Ito H, Iwakura K, et al. Usefulness of a new grading system based on coronary flow velocity pattern in predicting outcome in patients with acute myocardial infarction having percutaneous coronary intervention. Am J Cardiol 2005;96:927-32
44. Iwakura K, Ito H, Kawano S, et al. Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices. Eur Heart J 2004;25:1526-33.
45. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993-9.
46. Gibbons RJ. Infarct size measurement by single photon emission computed tomographic imaging with 99mTc-Sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000, 101:101-108.
47. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998;98:1006-14.
48. Matetzky S, Novikov M, Gruberg L, et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999; 34:1932-1938.
49. Anderson RD, White HD, Ohman EM, et al. Predicting outcome after thrombolysis in AMI according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Am Heart J 2002;144:81-8.
50. Desmet WJ, Mesotten LV, Maes AF, Heidbuchel HP, Mortelmans LA, Van de Werf FJ. Relation between different methods for analysing ST segment deviation and infarct size as assessed by positron emission tomography. Heart 2004; 90: 887-92.
51. Roe MT. Treatment Strategies for Microvascular Dysfunction Following Acute Myocardial Infarction. Current Cardiology Reports 2000;2:405-410
52. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000;101: 2734-41.
53. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-9.
54. Hang CL, Wang CP, Yip HK, et al. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest 2005;128:2593-8.
55. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003;42:1-6.
56. Heitzer T, Ollmann I, Koke K, Meinertz T, Munzel T. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation 2003;108:536-41.
57. Y-J Yang, J-L Zhao, S-J You, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 2006;92:1131-1137.
58. Uyarel H, Uzunlar B, Unal Dayi S, et al. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty. Cardiology 2006;105:168-75.
59. The PARADIGM Investigators: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998, 32:2003-2010.
60. Barrabes JA, Garcia-Dorado D, Soriano B, et al. Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. Cardiovasc Res 2000;47:265-73.
61. Mirabet M, Garcia-Dorado D, Inserte J, et al. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol 2002;283: H1134-41.
62. Ozer MK, Sahna E, Birincioglu M, Acet A. Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. Pharmacol Res 2002; 45: 257-63.
63. Zhu B, Sun Y, Sievers RE, et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 2000;35:787-95.
64. Jugdutt BI, Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem 2004;260:111-8.
65. Ryckwaert F, Colson P, Guillon G, Foex P. Cumulative effects of AT1 and AT2 receptor blockade on ischaemia-reperfusion recovery in rat hearts. Pharmacol Res 2005;51:497-502.
66. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
67. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003;41:649-56.
68. Iwakura K, Ito H, Kawano S, Okamura A, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-9.
69. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9.
70. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-20.
71. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004;68:928-32
72. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000; 35:345-351.
73. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol 2004;286:H1273-80.
74. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002; 40: 339-46.
75. Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997, 133: 616-621.
76. Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006; 70:1099-104.
77. Barrabes JA, Garcia-Dorado D, Mirabet M, et al. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol 2005; 45:293-9.
78. Zhao J, Yang Y, you S, Cui C, Gao R. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol 2007;115:334-41.
79. Ikeno F, Inagaki K, Rezaee M, Mochly-Rosen D. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res 2007;73:699-709.
80. Youssef AA, Wu CJ, Hang CL, et al. Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention. Circ J 2006;70:1538-42.
81. Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005; 95: 1358-61.
82. Matsuo A, Inoue N, Suzuki K, et al. Limitations of using a GuardWire temporary occlusion and aspiration system in patients with acute myocardial infarction: multicenter investigation of coronary artery protection with a distal occlusion device in acute myocardial infarction (MICADO). J Invasive Cardiol 2007;19: 132-8.
83. Limbruno U, Micheli A, De Carlo M, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003;108:171-6.
84. Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001;104: 2436-41.
85. Angelini A, Rubartelli P, Mistrorigo F, et al. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina. Circulation 2004;110: 515-21.
86. Umeda H, Katoh T, Iwase M, et al. The distal protection during primary percutaneous coronary intervention alleviates the adverse effects of large thrombus burden on myocardial reperfusion. Circ J 2006;70:232-8
87. Young JJ, Cox DA, Stuckey T, et al. Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. J Interv Cardiol 2007;20:44-50.
88. Amado LC, Kraitchman DL, Gerber BL, et al. Reduction of "no-reflow" phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J Am Coll Cardiol 2004; 43:1291-8.